IndustryCompany release

Ceribell Q3 revenue rises 30% to $29.3M and full-year guidance is lifted

🇺🇸 Ceribell, Inc. (CBLL) · Tue 03 Nov 2026

The EEG-based point-of-care company reported a 90% gross margin, launched its delirium monitoring solution in full and won two FDA 510(k) clearances.

Ceribell (Nasdaq: CBLL) reported third-quarter 2026 results on 3 November, with revenue of $29.3M, up 30% on the same period a year earlier. Gross margin was 90%, while the net loss for the quarter was $21.4M.

On the commercial side, the company has moved to a full launch of its delirium monitoring solution following a commercial pilot. The summary provided does not give details of the pilot's scope or results.

Ceribell also received FDA 510(k) clearance for two software capabilities: Quantitative EEG Trending and Amplitude-Integrated EEG Analysis. The 510(k) route is the US pathway under which a device is cleared on the basis of substantial equivalence to a legally marketed predicate device.

On financing, the company entered a credit facility in August 2026 that offers up to $60M in committed capital. Alongside the results, Ceribell raised its 2026 revenue outlook to a range of $115M to $117M.

What it means for your team

  • Regulatory teams tracking neurodiagnostic software should note the two new 510(k) clearances for EEG trending and analysis functions.
  • The full launch of delirium monitoring after a pilot shows how a new clinical indication can move from limited rollout to general commercial availability.
  • Market-access and hospital-contracting teams may see wider availability of the company's EEG offerings as the commercial rollout expands, although the source gives no detail on pricing or reimbursement.

Company's press release (SEC filing): Ceribell, Inc. ↗

Article written by VigiEye from the official source (Ceribell, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →